Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07921836
NA

Comparison of Two Probiotics for Reducing Diarrhea Frequency in Children Aged 6-24 Months

Sponsor: King Edward Medical University

View on ClinicalTrials.gov

Summary

Clinical Trial Summary The goal of this clinical trial is to compare the effectiveness of Saccharomyces boulardii CNCM I-745 and multi-strain Bacillus clausii in reducing the frequency of acute watery diarrhea in children aged 6 to 24 months. The main question it aims to answer is: \- Which probiotic is more effective in reducing the daily frequency of acute watery diarrhea in children? Researchers will compare Saccharomyces boulardii CNCM I-745 with a four-strain mixture of Bacillus clausii (O/C, SIN, N/R, T) to determine which is more effective in reducing diarrhea frequency. Participants will: * Receive either Saccharomyces boulardii CNCM I-745 at a daily dose of 10 billion CFU or multi-strain Bacillus clausii at a daily dose of 4 billion CFU for 3 days. * Receive standard treatment for diarrhea, including oral rehydration therapy (ORS), zinc supplementation, and dietary advice. * Be followed for 3 days after admission, with daily recording of the frequency of diarrhea episodes.

Official title: Comparison of the Effectiveness of Saccharomyces Boulardii CNCM I-745 and Multi-Strain Bacillus Clausii in Reducing the Frequency of Acute Watery Diarrhea in Children Aged 6 to 24 Months

Key Details

Gender

All

Age Range

6 Months - 24 Months

Study Type

INTERVENTIONAL

Enrollment

88

Start Date

2026-11

Completion Date

2027-02

Last Updated

2026-11-06

Healthy Volunteers

No

Interventions

DRUG

Saccharomyces boulardii CNCM I-745

Probiotic yeast preparation containing Saccharomyces boulardii CNCM I-745, administered orally at a daily dose of 10 billion colony-forming units (CFU) for 3 days.

DRUG

Bacillus clausii (O/C, SIN, N/R, T)

Four-strain probiotic preparation containing Bacillus clausii strains O/C, SIN, N/R, and T, administered orally at a daily dose of 4 billion colony-forming units (CFU) for 3 days.